Parkinson’s disease is the second most common neurodegenerative disease characterized by deteriorating of dopaminergic neurons in the substance of nigra and, consequently, lack of dopamine. Present therapies are focused on reduction of motoric symptoms and sadly lose their efficiency as the neurodegeneration and symtpoms progress. Levodopa is currently a gold standard for curing Parkinson’s disease, but long-term application results in various side effects. Curing neurodegenerative disorders is still a major challenge because of existing blood-brain barrier that complicates efficient transmission of medication into the brain. Nanomaterials have a potential to upgrade therapeutic approaches because of their ability to pass through the blood-brain barrier, to improve pharmacological profile and safety of drugs and to transport drugs to the targeted area. Selenium nanoparticles stabilized by polyvinylpyrrolidone and gold nanoparticles stabilized by peptidoglycan monomer are examined as carriers for the levodopa transmission, with the goal of achieving the neuroprotective effect. Their ability to reduce oxidative stress caused by levodopa is evaluated in an in vivo model of Parkinson’s disease. Rats of both sexes were distributed in 7 groups and tested with test subtances for 28 days. The distribution of animals to the groups was random. Oxidative stress is examined by measuring reactive oxygen species and concentration of glutathione in brain, kidney, liver and serum of non-treated and treated rats. Results indicate a neuroprotective impact of selenium nanoparticles. Gold nanoparticles did not provide protective effect and it is possible that their application has a negative toxicological effects.